Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AeroFact in Preterm Infants at Risk of Worsening RDS
NCT03969992Phase 2Completed
- Sponsor
- Aerogen
- Start
- Mar 2020
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of calfactant in respiratory distress syndrome (RDS) (3 arms), sponsored by Aerogen. Primary endpoint: Rate of Intubation/Cannulation and Bolus Surfactant Instillation. Started Mar 2020; status: completed.
02
Drugs
calfactant
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT03969992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969992.